# Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

> **NCT01829321** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 45 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** GLPG0974
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01829321
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829321, "Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01829321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*